Name of study:
ASPEN: Evaluate the effect of brensocatib at 10 mg and 25 mg compared with placebo on the rate of pulmonary exacerbations over the 52-week treatment period.
Targeted disease:
Non-Cystic Fibrosis Bronchiectasis
Purpose of study:
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy, Safety, and Tolerability of Brensocatib Administered Once Daily for 52 Weeks in Subjects with Non-Cystic Fibrosis Bronchiectasis
Is this a pre- or post- market study?:
Pre-Market Study
Is the study of a controlled or observational design?
Controlled
What is the funding source?:
Insmed Incorporated
Where is the study being conducted?
Multi-Center Trial
Lead Institution:
Multi-Center Trial
City and State:
Nationwide
When the study is being conducted:
Start Date:11/10/2020
End date: 3/31/2024
What website should a person use to register for the study?
https://www.patientwing.com/ASPEN-ALA
Who should a person contact to register for the study?
Name: PatientWing
Phone: (213) 549-2979
Email: [email protected]
Who is sponsoring this study?
Insmed Incorporated
What is the identifier for this study on ClinicalTrials.gov?
NCT04594369
Page last updated: February 23, 2021